DarioHealth Projected to Post $3.24/Share Loss, Revenue Down 33% Ahead of Earnings
summarizeSummary
Analysts are projecting DarioHealth Corp. to report a significant loss of $3.24 per share and a 33.6% decrease in revenue to $5.047 million for the fourth quarter of 2025. This earnings preview sets a negative expectation for the company's financial performance, contrasting with the recent positive news on March 3rd regarding increased demand for its oral GLP-1 solution. The anticipated substantial loss relative to the current stock price could weigh on investor sentiment and positioning ahead of the estimated earnings release on March 9th. Traders will closely watch the actual results and any forward guidance to see if the company can outperform these lowered expectations.
At the time of this announcement, DRIO was trading at $9.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $67.5M. The 52-week trading range was $5.94 to $17.74. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.